RRM1 antibody
GTX100758
ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetRRM1
Overview
- SupplierGeneTex
- Product NameRRM1 antibody
- Delivery Days Customer9
- Application Supplier NoteWB: 1:500-1:3000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsImmunoFluorescence, Western Blot, ImmunoCytoChemistry, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.49 mg/ml
- ConjugateUnconjugated
- Gene ID6240
- Target nameRRM1
- Target descriptionribonucleotide reductase catalytic subunit M1
- Target synonymsPEOB6, R1, RIR1, RR1, ribonucleoside-diphosphate reductase large subunit, ribonucleoside-diphosphate reductase subunit M1, ribonucleotide reductase M1 polypeptide, ribonucleotide reductase, R1 subunit
- HostRabbit
- IsotypeIgG
- Protein IDP23921
- Protein NameRibonucleoside-diphosphate reductase large subunit
- Scientific DescriptionThis gene encodes one of two non-identical subunits that constitute ribonucleoside-diphosphate reductase, an enzyme essential for the production of deoxyribonucleotides prior to DNA synthesis in S phase of dividing cells. It is one of several genes located in the imprinted gene domain of 11p15.5, an important tumor-suppressor gene region. Alterations in this region have been associated with the Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocrotical carcinoma, and lung, ovarian, and breast cancer. This gene may play a role in malignancies and disease that involve this region. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Muñoz-Montaño W, Muñiz-Hernández S, Avilés-Salas A, et al. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer. 2021,21(1):892. doi: 10.1186/s12885-021-08287-5Read this paper
- Wang X, Yamamoto Y, Imanishi M, et al. Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type TP53 colon and gastric cancer cells with aberrant KRAS signaling. Oncol Lett. 2021,22(1):558. doi: 10.3892/ol.2021.12819Read this paper




